Company intelligence / Profile preview

Olpha

Ownership: Private
Employees: ~900
Development stage: Commercial

Overview

Olpha (formerly Olainfarm) is a leading pharmaceutical manufacturer in the Baltic states with over 50 years of experience. The company produces and markets over 60 finished dosage forms, 25 active pharmaceutical ingredients, and more than 20 intermediates. They have successfully registered more than 50 new products and are expanding into Western markets.

Therapeutic areas: OncologyEndocrinologyImmunologyCardiovascularNeurologyInfectious Diseases
Modalities: Small moleculesActive Pharmaceutical Ingredients (APIs)Finished Dosage Forms (FDFs)
Industry: Biotech

Drug pipeline

3 assets

mebicar

Unknown

2 more assets in the full pipeline.

Request access →

Partnerships

NovartisDr. Reddy'sGlenmark GenericsSigma AUAlmirall RankeUQUIFAMIATActavisTevaEgisPHFWorld Health Organization

Beyond the preview

Go deeper on Olpha.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Olpha.

Explore the full profile